NEW FIBROBLAST GROWTH FACTOR (FGF23) AND METHOD OF USE

摘要

PROBLEM TO BE SOLVED: To provide a molecular marker useful for earlier diagnosing disorders in patients in a hypophosphatemic state and in a hyperphosphatemic state, classifying malignancy and classifying a stage of a disease and to provide a method for similarly and effectively treating patients of hypophosphatemic and hyperphosphatemic disorders.

SOLUTION: The new nucleic acid encodes a fibroblast growth factor-23 (FGF23) in which mutations are associated with autosomal dominant hypophosphatemic rickets (ADHR). The protein is encoded thereby. The method for diagnosing and treating hypophosphatemic and hyperphosphatemic disorders comprises inhibiting or stimulating, respectively, the biological activity of FGF23 in a patient. The method for treating osteoporosis, dermatomyositis and coronary artery disease comprises stimulating the biological activity of FGF23 in a patient.

COPYRIGHT: (C)2008,JPO&INPIT